A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Clinical trial NCT03412773 · COMPLETED

Trial details

NCT number: NCT03412773
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)

Start date: 2017-12-18
Primary completion: 2022-07-11
Enrollment: 684

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.